Top

Published in:

01-08-2018 | Original Article

BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

Authors: Jilei Zhang, Jinlong Shi, Gaoqi Zhang, Xinpei Zhang, Xinrui Yang, Siyuan Yang, Jing Wang, Xiaoyan Ke, Lin Fu

Published in: Annals of Hematology | Issue 8/2018

Abstract

Brain and acute leukemia, cytoplasmic (BAALC) and ETS-related gene (ERG) expression levels are independent prognostic factors for acute myeloid leukemia (AML); however, their prognostic impacts on AML patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) require further investigation. We studied 71 de novo AML patients treated with allo-HSCT and defined low and high expressers according to the median expression levels of BAALC and ERG at diagnosis respectively. High BAALC expression was associated with wild-type NPM1 (P = 0.000) and RUNX1 mutations (P = 0.027). High ERG expression was associated with FLT3-ITD absence (P = 0.003) and wild-type NPM1 (P = 0.001). BAALC and ERG expression levels were significantly correlated with each other (P = 0.001). Survival analyses including Kaplan-Meier curves and univariate and multivariate analysis consistently reported that there were no significant differences for both event-free survival (EFS) and overall survival (OS) (all P > 0.1), between high versus low BAALC and ERG expressers. Our study suggested that despite of their well-known adverse role in prognosis of AML, neither BAALC nor ERG expression levels at diagnosis had effect on survival of AML patients who underwent allo-HSCT.

Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373(12):1136–1152CrossRefPubMed

Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196 CrossRefPubMedPubMedCentral

Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115(3):453–474CrossRefPubMed

Tsai CH, Hou HA, Tang JL, Liu CY, Lin CC, Chou WC, Tseng MH, Chiang YC, Kuo YY, Liu MC, Liu CW, Lin LI, Tsay W, Yao M, Li CC, Huang SY, Ko BS, Hsu SC, Chen CY, Lin CT, Wu SJ, Tien HF (2016) Genetic alterations and their clinical implications in older patients with acute myeloid leukemia. Leukemia 30(7):1485–1492CrossRefPubMed

Thol F, Damm F, Ludeking A, Winschel C, Wagner K, Morgan M, Yun H, Gohring G, Schlegelberger B, Hoelzer D, Lubbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 29(21):2889–2896. https://doi.org/10.1200/jco.2011.35.4894 CrossRef

Meyer SC, Levine RL (2014) Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol 15(9):e382–e394CrossRefPubMed

Sanders MA, Valk PJ (2013) The evolving molecular genetic landscape in acute myeloid leukaemia. Curr Opin Hematol 20(2):79–85. https://doi.org/10.1097/MOH.0b013e32835d821c CrossRefPubMed

Mendler JH, Maharry K, Radmacher MD, Mrozek K, Becker H, Metzeler KH, Schwind S, Whitman SP, Khalife J, Kohlschmidt J, Nicolet D, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD (2012) RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 30(25):3109–3118. https://doi.org/10.1200/jco.2011.40.6652 CrossRef

Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL (2012) Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 366(12):1079–1089CrossRefPubMedPubMedCentral

10.

Xiao SJ, Shen JZ, Huang JL, Fu HY (2015) Prognostic significance of the BAALC gene expression in adult patients with acute myeloid leukemia: a meta-analysis. Molecular and clinical oncology 3(4):880–888. https://doi.org/10.3892/mco.2015.562 CrossRefPubMedPubMedCentral

11.

Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrozek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD (2010) BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 116(25):5660–5669. https://doi.org/10.1182/blood-2010-06-290536 CrossRefPubMedPubMedCentral

12.

Eid MA, Attia M, Abdou S, El-Shazly SF, Elahwal L, Farrag W, Mahmoud L (2010) BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis. Int J Lab Hematol 32(2):197–205. https://doi.org/10.1111/j.1751-553X.2009.01168.x CrossRefPubMed

13.

Tanner SM, Austin JL, Leone G, Rush LJ, Plass C, Heinonen K, Mrozek K, Sill H, Knuutila S, Kolitz JE, Archer KJ, Caligiuri MA, Bloomfield CD, de La Chapelle A (2001) BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A 98(24):13901–13906. https://doi.org/10.1073/pnas.241525498 CrossRefPubMedPubMedCentral

14.

Weber S, Haferlach T, Alpermann T, Perglerova K, Schnittger S, Haferlach C, Kern W (2016) Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia. Br J Haematol 175(5):904–916. https://doi.org/10.1111/bjh.14343 CrossRefPubMed

15.

Santamaria C, Chillon MC, Garcia-Sanz R, Perez C, Caballero MD, Mateos MV, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizan JA, Rodriguez JN, Puig N, Balanzategui A, Sarasquete ME, Alcoceba M, Diaz-Mediavilla J, San Miguel J, Gonzalez M (2010) BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann Hematol 89(5):453–458. https://doi.org/10.1007/s00277-009-0864-x CrossRefPubMed

16.

Damiani D, Tiribelli M, Franzoni A, Michelutti A, Fabbro D, Cavallin M, Toffoletti E, Simeone E, Fanin R, Damante G (2013) BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients. Am J Hematol 88(10):848–852. https://doi.org/10.1002/ajh.23516 CrossRefPubMed

17.

Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Lim JH (2014) Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia. Leukemia & lymphoma 55(1):110–120. https://doi.org/10.3109/10428194.2013.800869 CrossRef

18.

Marcucci G, Maharry K, Whitman SP, Vukosavljevic T, Paschka P, Langer C, Mrozek K, Baldus CD, Carroll AJ, Powell BL, Kolitz JE, Larson RA, Bloomfield CD (2007) High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25(22):3337–3343. https://doi.org/10.1200/jco.2007.10.8720 CrossRef

19.

Metzeler KH, Dufour A, Benthaus T, Hummel M, Sauerland MC, Heinecke A, Berdel WE, Buchner T, Wormann B, Mansmann U, Braess J, Spiekermann K, Hiddemann W, Buske C, Bohlander SK (2009) ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 27(30):5031–5038. https://doi.org/10.1200/jco.2008.20.5328 CrossRef

20.

Pan J, Zhang Y, Zhao YL, Yang JF, Zhang JP, Liu HX, Wu T, Tong CR (2017) Impact of clinical factors on outcome of leukemia patients with TLS-ERG fusion gene. Leukemia & lymphoma 58(7):1655–1663. https://doi.org/10.1080/10428194.2016.1260124 CrossRef

21.

Magenau J, Couriel DR (2013) Hematopoietic stem cell transplantation for acute myeloid leukemia: to whom, when, and how. Curr Oncol Rep 15(5):436–444. https://doi.org/10.1007/s11912-013-0340-6 CrossRefPubMed

22.

Yoon JH, Kim HJ, Shin SH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW, Lim JH (2013) BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML. Eur J Haematol 91(2):112–121. https://doi.org/10.1111/ejh.12142 CrossRefPubMed

23.

Qin YZ, Chen Y, Xu LP, Wang Y, Zhang XH, Chen H, Zhao XS, Liu KY, Huang XJ (2018) Outcome and minimal residual disease monitoring in patients with t(16,21) acute myelogenous leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 24(1):163–168. https://doi.org/10.1016/j.bbmt.2017.09.002 CrossRef

24.

Liu YC, Hsiao HH, Lin PM, Yang WC, Chang CS, Liu TC, Hsu JF, Yang MY, Lin SF (2013) Prognostic implication of molecular aberrations in cytogenetically normal acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation. Genetics and molecular research : GMR 12(4):5414–5423. https://doi.org/10.4238/2013.November.11.3 CrossRefPubMed

25.

Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R, Escoda L, Guardia R, Queipo de Llano MP, Salamero O, Bargay J, Pedro C, Marti JM, Torrebadell M, Diaz-Beya M, Camos M, Colomer D, Hoyos M, Sierra J, Esteve J (2013) Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 121(14):2734–2738. https://doi.org/10.1182/blood-2012-06-431122 CrossRefPubMed

26.

Baldus CD, Tanner SM, Ruppert AS, Whitman SP, Archer KJ, Marcucci G, Caligiuri MA, Carroll AJ, Vardiman JW, Powell BL, Allen SL, Moore JO, Larson RA, Kolitz JE, de la Chapelle A, Bloomfield CD (2003) BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B study. Blood 102(5):1613–1618. https://doi.org/10.1182/blood-2003-02-0359 CrossRefPubMed

27.

Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrozek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD (2008) High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111(11):5371–5379. https://doi.org/10.1182/blood-2007-11-124958 CrossRefPubMedPubMedCentral

28.

Hamalainen M, Juvonen V, Haikio S, Lakkala T, Johansson J, Pelliniemi TT, Salmi TT, Remes K, Kairisto V (2010) ETS-related gene ERG expression in AML patients is significantly associated with NPM1 mutation status. Eur J Haematol 85(4):361–362. https://doi.org/10.1111/j.1600-0609.2010.01483.x CrossRefPubMed

Title: BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation
Authors: Jilei Zhang
Jinlong Shi
Gaoqi Zhang
Xinpei Zhang
Xinrui Yang
Siyuan Yang
Jing Wang
Xiaoyan Ke
Lin Fu
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 8/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3331-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2018

Late-onset hemophagocytic lymphohistiocytosis with varicella zoster virus and Epstein-Barr virus co-infection after umbilical cord blood transplantation

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia

Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes

Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia

Diffuse large B cell lymphoma (DLBCL): bilateral vanishing tibiae

Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page